HealthNovo Nordisk Trial Finds Semaglutide Cuts BMI in Children Under 12By Naomi CalderNov 20, 2026, 6:11 PM UTC
HealthFDA Orders GLP-1 Drug Labels to Add Warning on Rare Eye RiskBy Naomi CalderNov 9, 2026, 7:44 PM UTC
HealthNovo Studies Link Semaglutide to Weight and Liver-Marker Changes in MASHBy Naomi CalderNov 7, 2026, 11:19 AM UTC
BusinessNovo Nordisk Raises 2026 Outlook as Obesity Sales Climb 22%By Helena WardNov 4, 2026, 10:38 AM UTC
HealthNovo’s AASLD Slate Pairs Wegovy Liver-Marker Data With Resmetirom ComparisonBy Naomi CalderOct 28, 2026, 4:24 PM UTC
HealthU.S. Employers Scale Back Some GLP-1 Coverage for 2027By Naomi CalderOct 27, 2026, 10:13 PM UTC